HUTCHMED (China) (HCM) Current Deferred Revenue (2016 - 2025)

HUTCHMED (China) (HCM) has disclosed Current Deferred Revenue for 9 consecutive years, with $31.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 37.26% to $31.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $31.4 million, a 37.26% decrease, with the full-year FY2025 number at $31.4 million, down 37.26% from a year prior.
  • Current Deferred Revenue was $31.4 million for Q4 2025 at HUTCHMED (China), down from $50.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $57.6 million in Q4 2023 to a low of $13.3 million in Q4 2022.
  • A 4-year average of $38.1 million and a median of $40.7 million in 2024 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: soared 331.85% in 2023, then crashed 37.26% in 2025.
  • HUTCHMED (China)'s Current Deferred Revenue stood at $13.3 million in 2022, then skyrocketed by 331.85% to $57.6 million in 2023, then dropped by 13.13% to $50.1 million in 2024, then crashed by 37.26% to $31.4 million in 2025.
  • Per Business Quant, the three most recent readings for HCM's Current Deferred Revenue are $31.4 million (Q4 2025), $50.1 million (Q4 2024), and $57.6 million (Q4 2023).